A Phase 1/Phase 2 Trial to Evaluate Safety, Immunogenicity and PSA Response of VTP-850 Prostate Cancer Immunotherapeutic in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
Latest Information Update: 14 May 2025
At a glance
Most Recent Events
- 07 May 2025 According to Barinthus Biotherapeutics media release, topline results from this study were received and analysis is ongoing.
- 19 Mar 2025 Status changed from active, no longer recruiting to discontinued.
- 10 Jan 2025 According to Barinthus Biotherapeutics media release, results from this trial are expected in Q2 2025.